Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Michael C Mithoefer, Charles S Grob, Timothy D Brewerton

4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) and methylenedioxyamphetamine (MDMA), best known for their illegal use as psychedelic drugs, are showing promise as therapeutics in a resurgence of clinical research during the past 10 years. Psilocybin is being tested for alcoholism, smoking cessation, and in patients with advanced cancer with anxiety. MDMA is showing encouraging results as a treatment for refractory post-traumatic stress disorder, social anxiety in autistic adults, and anxiety associated with a life-threatening illness. Both drugs are studied as adjuncts or catalysts to psychotherapy, rather than as stand-alone drug treatments. This model of drug-assisted psychotherapy is a possible alternative to existing pharmacological and psychological treatments in psychiatry. Further research is needed to fully assess the potential of these compounds in the management of these common disorders that are difficult to treat with existing methods.

Introduction

Advances in psychopharmacology during the past 60 years have benefited millions of patients with debilitating but common psychiatric disorders. However, approved psychopharmacological drugs have fallen short of definitively correcting underlying pathology and curing psychiatric illness. Antipsychotics, antidepressants, anxiolytics, and mood stabilisers can help to decrease symptoms, and can even be life-saving for some patients; however, for many, the benefits are disappointing, and the side-effects of long-term daily use can be problematic. Advances in evidence-based psychotherapy have yielded improved treatments for several disorders, including post-traumatic stress disorder (PTSD) and anxiety associated with life-threatening illness. Psychological treatments seem to be more effective than medications for PTSD; however, a large percentage of patients do not respond adequately to psychotherapy, with or without concomitant medications. Interest is also growing in development of more effective psychotherapy for existential suffering at the end of life. Research into methods to improve psychological treatments is especially important in view of a 2013 meta-analysis reporting that patients’ preference for psychotherapy is three times greater than for medication.

In our experience, most clinicians who treat psychiatric patients are all too familiar with the suffering and frustration endured by those who try successive medications, often with several drugs, but do not find relief or cannot tolerate the side-effects. Likewise, patients frequently do not make adequate progress in psychotherapy, or drop out because they are not able to tolerate emotionally challenging aspects of treatment such as prolonged exposure. The need for new approaches to psychological treatments is clear. The limitations of existing pharmacotherapy and psychotherapy and the paucity of resources for psychotherapy research and treatment leave millions of psychiatric patients suffering, and psychiatrists are faced with what has been called psychiatry’s identity crisis.

A promising new model of treatment is under investigation in a resurgence of research into use of psychedelic drugs to augment psychotherapy. In this model, the drug is used on one or a few occasions during psychotherapy sessions to overcome obstacles to successful psychotherapy and to catalyse a therapeutic experience. It is theorised that the experience itself, rather than simply the pharmacological effects of the drug, might lead to cure or sustained remission of severe, treatment-refractory psychiatric disorders. Results of both early and recent studies of 4-phosphorloxy-N,N-dimethyltryptamine (psilocybin) or methylenedioxyamphetamine (MDMA) in conjunction with psychotherapy offer the possibility of rapid, comprehensive, and lasting psychological healing and growth, and raise many intriguing questions about the mechanisms and clinical applicability of this model of treatment. Therapeutic approaches used in psilocybin and MDMA studies overlap substantially, but the two drugs have been studied for different indications in most cases. Both approaches include inner focus and talking with therapists; however, in MDMA-assisted sessions, periods of talking generally alternate with periods of inner focus, whereas in psilocybin-assisted sessions, most of the talking occurs before and after the period of drug effect. We discuss psilocybin and MDMA separately.

Psilocybin-assisted psychotherapy

The classic hallucinogen psilocybin exists in nature as an active alkaloid in more than 100 species of mushrooms. Although used for healing and divination in many indigenous cultures in South and Central America, psilocybin was not discovered by Western cultures until the 1950s. During the 1950s to early 1970s, together with the better known lysergic acid diethylamide (LSD), psilocybin was used in investigations in human beings. In addition to their range of effects on CNS function, psilocybin and LSD had promising therapeutic potential in preliminary studies, most interestingly in patients with various treatment-refractory disorders. Unfortunately, these studies were brought to an abrupt halt, as a result of the notorious so-called culture wars of that era.

P.S.: This work is supported by the Robert J. and Helen R. Smith Foundation and the University of South Carolina College of Arts and Sciences. MCM is the founder of Research Triangle Institute, a non-profit research organization. CSG is on the board of directors for the California Institute for Integral Studies. The authors declare no other conflicts of interest.
One population in which this novel psychedelic treatment model is showing promising results, and for whom conventional treatments have long been known to be inadequate, are patients with advanced-stage cancer with severe reactive anxiety. Results of a series of studies done several decades ago showed substantive and sustained reductions in anxiety, improved mood, and enhanced quality of life in patients with terminal cancer after one closely monitored dose of LSD or di-propyltryptamine (DPT), a compound chemically related to psilocybin.9 More recent investigations have corroborated these early findings, with moderate-dose psilocybin as the active agent for a one-session treatment model (table 1).10–13

The first study in more than 30 years to investigate the potential of a classic hallucinogen treatment model in patients with advanced cancer and anxiety, at Harbor-UCLA Medical Center (Torrance, CA, USA) and supported by the Heffter Research Institute (Santa Fe, NM, USA), used a double-blind, placebo-controlled research model.11 12 patients functioning as their own controls were given two separate experimental treatment sessions 1 month apart, receiving the active drug, psilocybin, on one occasion and placebo on the other, in a random order. All patients were screened and prepared through several meetings with treatment staff to establish rapport and acquire understanding of the range of altered states of consciousness that they might encounter during their treatment sessions. Follow-up data were collected for 6 months after the second treatment session. Results included safe physiological and psychological responses during treatment sessions. No clinically significant adverse events were noted. Significant reductions in anxiety at 1 month and 3 months after treatment were measured with the State-Trait Anxiety Inventory trait anxiety subscale, and an improvement of mood was measured with the Beck Depression Inventory, which reached significance at 6 months. For this first investigation of use of a classic hallucinogen treatment in several decades, a moderate dose of 0·2 mg/kg bodyweight was used. Subsequently, two other research groups, at Johns Hopkins University (Baltimore, MD, USA) and New York University (New York, NY, USA), have received approval from the US Food and Drug Administration (FDA) to use a higher dose in a similar population of patients. Publication of the results of these larger-scale studies is expected to be forthcoming (Roland Griffiths [Johns Hopkins University School of Medicine, Baltimore, MD, USA] and Stephen Ross [New York University, New York, NY, USA], personal communication). A similar study in Switzerland with LSD rather than psilocybin showed a strong effect size in reduction of state and trait anxiety.14

One line of inquiry that has emerged from research done in the 1960s15 has been the study of the range of profound psychospiritual experiences that might be induced by psychedelic drugs when administered under optimal conditions (set and setting), and their role in achieving therapeutic outcomes.16–17 The capacity to activate innate mechanisms for psychospiritual healing, especially in individuals with life-threatening medical illness and severe existential anxiety, depression, and demoralisation, might be an important advance for the healing arts and medicine. This shift is taking place in the context of major developments in neurotheology, which are elucidating the biological or brain basis of religious or spiritual experiences.18

Results of carefully undertaken studies at Johns Hopkins University showed that screened healthy volunteers treated under optimal conditions with high-dose psilocybin reliably experienced profound mystical experiences (defined as encountering a profound sense of unity, transcendence of time and space, deeply felt positive mood, noetic quality, ineffability, transiency, and paradoxicality) infused with a renewed sense of purpose and meaning, that even more than a year later retained their personal value.19–21 The association between psychedelic-induced mystical experience and therapeutic outcome when psychedelic drugs are given under optimal conditions provides a potentially valuable therapeutic intervention for disorders that are otherwise difficult to treat, including end-of-life anxiety and alcoholism—a very dangerous disorder with high rates of resistance to existing treatments, and the focus of several promising research studies starting in the 1950s and continuing until the early 1970s.22–23 This strategy has also been studied as part of a potential treatment model at the University of New Mexico (Albuquerque, NM, USA) and New York University. For example, Bogenschutz and colleagues24 showed that a single dose of psilocybin resulted in reductions in drinking behaviour and craving in ten individuals with alcohol use disorder. In a pilot

Table 1: Phase 2 studies of psilocybin-assisted psychotherapy

<table>
<thead>
<tr>
<th>Location</th>
<th>Status</th>
<th>Sample size</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Arizona (Tucson, AZ, USA)</td>
<td>Complete 9</td>
<td>Results published in 2006</td>
<td></td>
</tr>
<tr>
<td>Cancer anxiety (ClinicalTrials.gov, number NCT00465595)</td>
<td>Complete 12</td>
<td>Results published in 2011</td>
<td></td>
</tr>
<tr>
<td>Johns Hopkins University (Baltimore, MD, USA)</td>
<td>Complete 51</td>
<td>Results submitted for publication</td>
<td></td>
</tr>
<tr>
<td>New York University (New York, NY, USA)</td>
<td>Complete 31</td>
<td>Results submitted for publication</td>
<td></td>
</tr>
<tr>
<td>University of New Mexico (Albuquerque, NM, USA)</td>
<td>Complete 10</td>
<td>Results published in 2015</td>
<td></td>
</tr>
<tr>
<td>New York University (New York, NY, USA)</td>
<td>Ongoing 180</td>
<td>Expected completion 2016</td>
<td></td>
</tr>
<tr>
<td>Johns Hopkins University (Baltimore, MD, USA)</td>
<td>Complete 15</td>
<td>Results published in 2014</td>
<td></td>
</tr>
<tr>
<td>University of Alabama (Tuscaloosa, AL, USA)</td>
<td>Ongoing 40</td>
<td>Estimated completion May, 2017</td>
<td></td>
</tr>
</tbody>
</table>

Psilocybin=4-phosphofoxy-N,N-dimethyltryptamine.
study, Johnson and colleagues\(^4\) reported a substantially increased smoking cessation rate and improvement in biomarkers assessing smoking status after psilocybin treatment. 12 (80%) of 15 participants showed 7-day point prevalence abstinence in self-report measures of smoking behaviour at 6-month follow-up. If replicated in large and rigorous future studies, such impressive results would have enormous public health implications, in view of the high mortality associated with tobacco, which is several times higher than that of all other drugs of abuse combined, including alcohol.

The neuropsychopharmacological mechanisms of action of psilocybin and other similar psychedelic drugs are thought to be mediated via fairly specific binding to serotonergic 5-HT\(_2\)A receptors, primarily 5-HT\(_2\)A receptors, although non-5-HT\(_2\)A receptors are probably also involved.\(^24,25\) Downregulation of 5-HT\(_2\)A receptors mediates antidepressant and antianxiety effects of antidepressants and atypical antipsychotics.\(^26\) Because of the high binding affinity of psilocybin and other psychedelic drugs to the 5-HT\(_2\)A receptor, it might produce its effects in human beings mostly, but not wholly, through modulation of 5-HT\(_2\)A receptors, in addition to complex downstream second messenger signalling and gene-expression effects.\(^27,28\)

In view of the long-standing Western cultural reputation of psychedelic drugs as dangerous drugs of abuse, when taken recreationally by vulnerable individuals under uncontrolled and high-risk conditions, to establish and maintain strong safety parameters is essential when undertaking modern, approved research into the therapeutic potential of psychedelic drugs. Careful investigation of the extensive psychiatric research record with psychedelic drugs from the 1950s to early 1970s identified an extremely small number of adverse outcomes in formal research studies.\(^29,30\) An important contribution by the Johns Hopkins psilocybin research group is a set of safety guidelines for clinical research with hallucinogens,\(^31\) which should be used as standard in this rapidly changing field. Careful screening and monitoring, specifically for underlying psychological and cardiovascular vulnerabilities, substantially reduce risks incurred by unwitting recreational users.

**MDMA-assisted psychotherapy**

MDMA has become infamous for its use as the purported ingredient in recreational ecstasy, although results of surveys have shown that drugs other than MDMA were present in a high proportion of collected samples.\(^32-34\) Less well known is that in the late 1970s and early 1980s, before MDMA became an illegal Schedule 1 compound, it was used in conjunction with psychotherapy by an estimated 4000 psychiatrists and psychologists.\(^35\) MDMA has been called an entactogen, meaning literally “to produce touching within”, referring to its tendency to enhance inner awareness and distinguishing it from classic psychedelic drugs such as psilocybin.\(^36,37\) Case reports of successful clinical use were published, but no controlled research was done at that time.\(^38,39\) Descriptions of the therapeutic process catalysed by MDMA suggested that it might be especially useful for treatment of PTSD. For example, Greer and Tolbert\(^40\) stated that, “clients found it comfortable to be aware of, to communicate, and to remember thoughts and feelings that are usually accompanied by fear and anxiety”.

Because of the urgent public health need for a wider range of effective PTSD treatments, these promising reports should have quickly led to formal investigations of the potential risks and benefits of MDMA as a therapeutic agent. Unfortunately, a hostile regulatory and funding climate inhibited research of MDMA treatment for nearly 20 years. Meanwhile, a large amount of money has been spent worldwide on preclinical research, retrospective studies in recreational ecstasy users, and a few phase 1 trials in healthy volunteers assessing the risks of MDMA without investigation of the possible benefits. From the mid-1980s to early 2000s, substantial US National Institutes of Health (NIH) investment was made to investigate serotonin and dopamine neurotoxicity induced by MDMA, in animals and human beings, although careful inspection of many of these studies identified flaws in the methods.\(^41-43\) Fortunately, now that the benefits as well as the risks are being studied with rigorous research designs, existing preclinical and retrospective data are available to the non-profit research sponsors who have taken up the effort. As a result, far more is known about the range of effects and the risks of MDMA, which has been taken by millions of people worldwide, than about usual investigational new drugs.

A comprehensive discussion of MDMA toxicity is beyond the scope of this Personal View, and possible neurotoxic effects in recreational users are still under debate. When used in high-risk contexts, MDMA can be dangerous, and rarely recreational users have died, usually of heat stroke and dehydration during raves or of brain oedema from over-hydration in an ill-informed attempt to avoid dehydration. A specific area of concern regarding possible MDMA toxicity comes from studies of recreational users, some of whom performed more poorly on memory tests than did controls who did not use drugs.\(^44\) Almost all studies in this population have been retrospective, and are fraught with problems with methods, such as polydrug use and uncertainty about the composition of drugs taken.\(^45-47\)

The study best designed to minimise these confounders identified “little evidence of decreased cognitive performance in ecstasy users, save for poorer strategic self-regulation... [that] might have reflected a pre-morbid attribute of ecstasy users”.\(^48\) This subject has been debated at length in the medical literature, and the most evidence supports continued investigation of the therapeutic benefits of MDMA (reviewed by Doblin and colleagues).\(^49\) Many approved and clinically useful psychiatric medications are well known to have dose-dependent and frequency-dependent neurotoxic effects. The risks of these drugs are
often judged to be acceptable compared with the untreated disease state in question. MDMA and psilocybin have the advantage of being given only once or a few times rather than daily for months or years.

What is most relevant to risk/benefit calculations for clinical research and possible clinical use is evidence that pure MDMA in moderate doses can be given safely to individuals participating in clinical trials in controlled medical settings. More than 1100 individuals have received MDMA in phase 1 or phase 2 clinical trials so far without any unexpected drug-related serious adverse events. The only drug-related serious adverse event reported was a transient increase in pre-existing ventricular ectopy requiring overnight observation; there was no associated cardiac disease identified on further cardiac work-up. A phase 2 study in patients with PTSD that included neuropsychological testing before and after two doses of MDMA or inactive placebo reported no evidence of impairment.49

So far, two phase 2 clinical trials testing MDMA-assisted psychotherapy for treatment-resistant PTSD have been completed. In view of their encouraging results, these double-blind, placebo-controlled trials support the hypothesis that MDMA, used as a catalyst to psychotherapy, can be effective in treatment of PTSD in patients who did not respond to previous psychotherapy or medications. Similar additional trials are underway in the USA, (ClinicalTrials.gov, numbers NCT01458327, NCT01211405, and NCT01793610), Canada (ClinicalTrials.gov, number NCT01958593), and Israel (ClinicalTrials.gov, number NCT01689740). An earlier phase 2 dose-escalation trial started in Spain in 2000, but was terminated because pressure from the Madrid Anti-Drug Authority led to permission to use the study site being revoked. No medical or scientific reasons existed for termination of the study.52

In the first completed phase 2 trial, in 20 patients who had not responded to both psychotherapy and pharmacotherapy (with average duration of PTSD of >20 years), participants randomly assigned to MDMA with psychotherapy had significantly greater decreases in PTSD symptoms than did participants assigned to receive inactive placebo with the same psychotherapy, and 83% no longer met criteria for PTSD, compared with 25% of placebo participants.49 When seven of the eight patients in the placebo group subsequently received MDMA-assisted psychotherapy in an open-label crossover group, they all achieved roughly the same level of improvement as the original MDMA group. A long-term follow-up study a mean of 45-4 months (range 17-74, SD 17-3) later reported that at least 74% had durable remission of PTSD symptoms.50 A similar study in Switzerland with 12 patients did not reach statistical significance in Clinician Administered PTSD Scale score reductions, but nevertheless did have a strong effect size of more than 1, and showed significant reductions in the Posttraumatic Diagnostic Scale.50,51

The success of MDMA-assisted psychotherapy in these studies was not simply due to replacing one form of psychotherapy with another, or one drug with a more effective drug; rather it is an altogether different approach that could apply to various psychoactive compounds. This approach involves use of a drug to support and catalyse a more effective therapeutic process by stimulating access to an individual’s innate ability to engage in his or her own unique course of healing. Participants in these clinical trials, in addition to showing improvements in validated measures of PTSD symptoms, often report deeply meaningful therapeutic experiences and ensuing improvements in various areas of their lives. On long-term follow-up questionnaires, most participants endorsed benefits such as “increased self-awareness and understanding” and “enhanced spiritual life”.50 These responses suggest a subjectively authentic process of psychological and spiritual exploration and growth that could logically be expected to enable trauma processing and symptom reduction, and to promote healthy psychological development.

These results are based not on daily medication doses, but on two or three doses of MDMA, spaced several weeks apart, during 8-h psychotherapy sessions in which periods of inner focus are as important as periods of interaction with the therapists. Furthermore, the therapeutic process is not limited to the period of drug effect (MDMA has a half-life of about 8 h),50 but continues over time.50 Accordingly, MDMA research protocols include follow-up non-drug psychotherapy sessions to support the ongoing lessons and challenges of integrating the resulting psychological changes into daily life.

The mechanism of action of MDMA as a catalyst to psychotherapy is the subject of ongoing research, so our observations about it are speculative. During MDMA-assisted psychotherapy sessions, we observe a decrease in avoidance and defensiveness accompanied by clearer memory of past events, and willingness and ability to process them. Additionally, MDMA research participants often show a new awareness of their own counterproductive patterns of emotional and cognitive response to trauma, and a capacity for fearless and compassionate reappraisal— in many ways the ideal effects to augment psychotherapy. MDMA does not make revisiting traumatic memories easy, and certainly not ecstatic, but it can make it possible for individuals who had not been able to process trauma effectively during months or years of psychotherapy. This effect can be conceptualised in various ways: that the prosocial effects of MDMA might improve the therapeutic alliance with patients who have difficulty trusting; that MDMA in a therapeutic set and setting provides several hours in the optimal arousal zone, during which therapeutic change is possible;51 that MDMA enables memory retrieval and reconsolidation with new associations to safety; or that MDMA causes a shift from constrained styles of thinking to less rigid, unrestrained thinking.50 Each of these concepts is consistent with what is known about the physiological
effects of MDMA, which include: release and reuptake inhibition of serotonin, and to a lesser extent dopamine and norepinephrine; release of oxytocin and prolactin; decreased activity in amygdala and hippocampus, and perhaps increased activity in medial prefrontal cortex; increase in resting state functional connectivity (RSFC) between amygdala and hippocampus; and decreased RSFC between ventromedial prefrontal cortex and posterior cingulate cortex. Additionally, healthy volunteers given MDMA have reported a less negative response to worst autobiographical memories, and fMRI data showed attenuated activation to worst memories in the left anterior temporal cortex. Several studies are underway to further elucidate MDMA’s therapeutic mechanisms. A substudy of MP-8 (table 2) has examined fMRI with trauma script exposure before and after MDMA-assisted psychotherapy (results pending; ClinicalTrials.gov, number NCT02102802), and another study of individuals with PTSD examining fMRI with trauma script exposure during peak MDMA effects is planned at Cardiff University (Ben Sessa, Imperial College London, London, UK, and Cardiff University, Cardiff, Wales, UK, personal communication).

An additional group of patients in whom an MDMA treatment model is being investigated are adults on the autistic spectrum with social anxiety. An ongoing FDA-approved double-blind, placebo-controlled study (ClinicalTrials.gov, number NCT02008396) is using two closely monitored sessions of moderate-dose MDMA in a screened population naive to the drug. Although outcome data are masked until the conclusion of the study, physiological and psychological safety have thus far been carefully monitored and maintained. In addition to clinical outcomes, primarily social anxiety, the study is also assessing the roles of the neurohormones oxytocin and vasopressin, which have been reported to be sensitive to MDMA and have a role in interpersonal connections and bonding.

Relation to other methods of psychotherapy

MDMA-assisted psychotherapy and psilocybin-assisted psychotherapy clearly differ in many ways from most established methods of psychotherapy. The structure, including 8-h psychotherapy sessions, is unusual, and therapists take a fairly non-directive approach. However, to think that what happens in MDMA-assisted sessions would be unfamiliar to therapists experienced in other methods, or that MDMA might be incompatible with various existing therapies, would be a mistake. MDMA-assisted sessions often include imaginal exposure, correction of cognitive distortions, insights about psycho-dynamics and transference, and other recognisable therapeutic elements. In MDMA-assisted sessions, these elements often occur spontaneously with little or no direction from therapists. The therapeutic method used in MDMA studies is described in detail in our Treatment Manual, and overlap with other therapies has previously been discussed.

Challenges related to masking

The prominent subjective and objective effects of MDMA and psilocybin make masking of investigators and research participants more difficult than it is in studies of many other classes of drugs. Attempts to address this problem by use of low doses of MDMA as an active placebo have had little success (ClinicalTrials.gov, numbers NCT01211405, NCT01793610). Use of other active placebos has been an important aspect of research methods in most recent psilocybin studies. Some of the psilocybin pilot treatment studies were open label, whereas others have used various active placebos. Effective masking of independent raters has been much easier to accomplish, and could be strengthened further in phase 3 trials by randomly assigning each assessment to a blinded rater from a centralised pool.

Summary

In order for medical interventions to be based on valid science, clinical trials should be rigorously designed and undertaken. It is also essential that pursuit of research into promising potential treatments is neither neglected nor blocked by outside forces. In our view, psychedelic research should be pursued as expeditiously as possible. When people are suffering and medicine does not have an adequate response, many will seek alternative treatments. Ideally, patients should be able to go to their physicians for scientifically based guidance and access to the most effective treatments; however, many patients...
Panel: Priorities for the next 5 years of MDMA and psilocybin research

- Completion of ongoing phase 2 trials
- Phase 3 trials of safety and efficacy for specific indications (post-traumatic stress disorder, anxiety associated with cancer or severe medical illness, addictions)
- Strengthening of masking of independent outcome raters by use of centralised pools of raters for phase 3 trials
- Expanded research into neuropsychopharmacological mechanisms of action
- Qualitative research into phenomenology of therapeutic experiences in MDMA-assisted or psilocybin-assisted psychotherapy
- Investigation of MDMA in conjunction with various methods of psychotherapy, including established methods

Search strategy and selection criteria

Most of the references cited were known to the authors either because they were included in the Investigators Brochure for the author’s Investigational New Drug research, were written by the authors, or were read in preparation for the American Psychiatric Association Symposium on which this manuscript is based. Any additional searches were done with PubMed or Google Scholar. These searches were not planned and were done when necessary to answer a specific question.

Contributors

All authors contributed equally to this manuscript.

Declaration of interests

MCM reports non-financial support and personal fees from the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501c3 non-profit organisation and its subsidiary, MAPS Public Benefit Corporation. CSG reports Research funding from the Heffter Research Institute and MAPS. Neither funding source influenced the contents of this manuscript. TDB declares no competing interests.

Acknowledgments

We thank Lisa Jerome (the Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA, USA) for her helpful comments on previous versions of the manuscript and her expert assistance in compiling and formatting the references.

References


Cohen S. Lysergic acid diethylamide: side effects and complications.

J New Ment Dis 1960; 130: 30–40.


Tanner-Smith EE. Pharmacological content of tablets sold as “ecstasy”: results from an online testing service. *Drug Alcohol Depend* 2006; 83: 247–54.


Chabrol H, Oehen P. MDMA assisted psychotherapy found to have a large effect for chronic post-traumatic stress disorder. *J Psychopharmacol* 2013; 27: 865–66.


Milhoefer M. MDMA-assisted psychotherapy: how different is it from other psychotherapy? *MAPS Bulletin* 2013; 23: 10–14.